The Use of Bone-Turnover Markers in Asia-Pacific Populations

키워드

참고문헌 (55)

1. Vasikaran S, "Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment : a need for international reference standards", Osteoporos Int, 22, pp.391~420 (2011)
2. Delmas PD, "The use of biochemical markers of bone turnover in osteoporosis", Osteoporos Int, 11(Suppl 6), pp.S2~S17 (2000)
3. Kidney Disease : Improving Global Outcomes(KDIGO)CKD-MBD Update Work Group, "KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder(CKD-MBD)", Kidney Int Suppl(2011), 7, pp.1~59 (2017)
4. Peach H, "Value of plasma calcium, phosphate, and alkaline phosphatase measurements in the diagnosis of histological osteomalacia", J Clin Pathol, 35, pp.625~630 (1982)
5. Ralston SH, "Diagnosis and management of Paget’s disease of bone in adults : a clinical guideline", J Bone Miner Res, 34, pp.579~604 (2019)
6. Alonso S, "The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy", J Endocrinol Invest, 35, pp.640~644 (2012)
7. Yang L, "Pediatric reference intervals for bone markers", Clin Biochem, 39, pp.561~568 (2006)
8. Tobiume H, "Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone(GH)deficiency : a potential marker for bone formation and response to GH therapy", J Clin Endocrinol Metab, 82, pp.2056~2061 (1997)
9. Pi YZ, "Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women", J Bone Miner Metab, 24, pp.380~385 (2006)
10. Szulc P, "Biochemical measurements of bone turnover in children and adolescents", Osteoporos Int, 11, pp.281~294 (2000)
11. Braga V, "Bone turnover markers in patients with osteogenesis imperfecta", Bone, 34, pp.1013~1016 (2004)
12. Chubb SAP, "Reference intervals for plasma β-CTX and P1NP in children : a systematic review and pooled estimates", Clin Biochem, 118, pp.110582~ (2023)
13. Hoshino H, "Changes in levels of biochemical markers and ultrasound indices of Os calcis across the menopausal transition", Osteoporos Int, 11, pp.128~133 (2000)
14. Heaney RP, "Menopausal changes in bone remodeling", J Lab Clin Med, 92, pp.964~970 (1978)
15. Naylor K, "Bone turnover markers : use in osteoporosis", Nat Rev Rheumatol, 8, pp.379~389 (2012)
16. Morris HA, "Clinical usefulness of bone turnover marker concentrations in osteoporosis", Clin Chim Acta, 467, pp.34~41 (2017)
17. Cho DH, "Reference intervals for bone turnover markers in Korean healthy women", J Bone Metab, 27, pp.43~52 (2020)
18. Yoo JI, "Age-related reference intervals for total collagen-I-N-terminal propeptide in healthy Korean population", J Bone Metab, 25, pp.235~241 (2018)
19. Hu WW, "Establishing reference intervals for bone turnover markers in the healthy Shanghai population and the relationship with bone mineral density in postmenopausal women", Int J Endocrinol, 2013, pp.513925~ (2013)
20. Li M, "Chinese bone turnover marker study : reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender", PLoS One, 9, pp.e103841~ (2014)
21. Sun LL, "Establishment of reference intervals for bone turnover markers in healthy Chinese older adults", Ann Hum Biol, 50, pp.172~186 (2023)
22. Nishizawa Y, "Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis(2018 Edition)", Clin Chim Acta, 498, pp.101~107 (2019)
23. Wu CH, "Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific region", J Clin Densitom, 24, pp.3~13 (2021)
24. Park SY, "Position statement on the use of bone turnover markers for osteoporosis treatment", J Bone Metab, 26, pp.213~224 (2019)
25. Vasikaran SD, "Practical considerations for the clinical application of bone turnover markers in osteoporosis", Calcif Tissue Int, 112, pp.148~157 (2023)
26. Vasikaran SD, "The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis", Endocrine, 52, pp.222~225 (2016)
27. Eastell R, "How to interpret surrogate markers of efficacy in osteoporosis", J Bone Miner Res, 20, pp.1261~1262 (2005)
28. Vasikaran SD, "Intra-individual variation in fasting urinary calcium-and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients", Ann Clin Biochem, 31, pp.272~276 (1994)
29. Szulc P, "Use of CTX-I and PINP as bone turnover markers : National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability", Osteoporos Int, 28, pp.2541~2556 (2017)
30. Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)
31. Chandran M, "IQ driving QI : the Asia Pacific Consortium on Osteoporosis(APCO) : an innovative and collaborative initiative to improve osteoporosis care in the Asia Pacific", Osteoporos Int, 31, pp.2077~2081 (2020)
32. Mithal A, "The Asia-Pacific regional auditepidemiology, costs, and burden of osteoporosis in India 2013: a report of International Osteoporosis Foundation", Indian J Endocrinol Metab, 18, pp.449~454 (2014)
33. Garnero P, "Markers of bone resorption predict hip fracture in elderly women : the EPIDOS Prospective Study", J Bone Miner Res, 11, pp.1531~1538 (1996)
34. Garnero P, "Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study", J Bone Miner Res, 15, pp.1526~1536 (2000)
35. McCloskey EV, "Official positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®", J Clin Densitom, 14, pp.220~222 (2011)
36. Reginster JY, "Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy", Bone, 42, pp.832~836 (2008)
37. Eastell R, "Diagnosis of endocrine disease : bone turnover markers : are they clinically useful?", Eur J Endocrinol, 178, pp.R19~R31 (2018)
38. Lorentzon M, "Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis", Adv Ther, 36, pp.2811~2824 (2019)
39. Meier C, "Biochemical markers of bone fragility in patients with diabetes. A narrative review by the IOF and the ECTS", J Clin Endocrinol Metab, pp.dgad255~ (2023)
40. Krege JH, "PINP as a biological response marker during teriparatide treatment for osteoporosis", Osteoporos Int, 25, pp.2159~2171 (2014)
41. Bone HG, "Ten years’ experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004)
42. Grey A, "Five years of anti-resorptive activity after a single dose of zoledronate — results from a randomized double-blind placebo-controlled trial", Bone, 50, pp.1389~1393 (2012)
43. Adler RA, "Managing osteoporosis in patients on long-term bisphosphonate treatment : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 31, pp.16~35 (2016)
44. Bauer DC, "Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy : the FLEX study", JAMA Intern Med, 174, pp.1126~1134 (2014)
45. Cosman F, "Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid : when is it reasonable to discontinue treatment?", J Clin Endocrinol Metab, 99, pp.4546~4554 (2014)
46. Bone HG, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", J Clin Endocrinol Metab, 96, pp.972~980 (2011)
47. Zanchetta MB, "Significant bone loss after stopping long-term denosumab treatment : a post FREEDOM study", Osteoporos Int, 29, pp.41~47 (2018)
48. Tsourdi E, "Fracture risk and management of discontinuation of denosumab therapy : a systematic review and position statement by ECTS", J Clin Endocrinol Metab, pp.dgaa756~ (2020)
49. Alvarez L, "Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover", J Bone Miner Metab, 22, pp.254~259 (2004)
50. Tridimas A, "Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide(PINP) : the choice of assay makes a difference", Ann Clin Biochem, 58, pp.528~536 (2021)
51. Sprague SM, "Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis", Am J Kidney Dis, 67, pp.559~566 (2016)
52. Salam S, "Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy", J Am Soc Nephrol, 29, pp.1557~1565 (2018)
53. Pimentel A, "Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation", Kidney Int, 92, pp.1343~1355 (2017)
54. Schini M, "Bone turnover markers : basic biology to clinical applications", Endocr Rev, 44, pp.417~473 (2023)
55. Bhattoa HP, "Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood", Clin Chim Acta, 515, pp.16~20 (2021)

관련 논문AI추천